• Platform
  • Pipeline
    • Overview
    • Clinical Trial
  • Team
    • Leadership
    • Board of Directors
  • News
  • Careers

Delivering on the Promise of Genetic Medicine for Every Patient

Kelonia Therapeutics Platform

Kelonia’s iGPS® technology builds on decades of research, development, and technical experience to efficiently deliver genetic cargo only to the desired tissue.

View our Platform

Press Release

See All Press Release

Kelonia Therapeutics Enters into Strategic Collaboration with Johnson & Johnson to Advance in vivo CAR-T Therapies

Read More

Kelonia Therapeutics Doses First Patient in Phase 1 inMMyCAR Study Evaluating in vivo CAR T-Cell Therapy for Relapsed and Refractory Multiple Myeloma

Read More

Kelonia Therapeutics to Present iGPS® Preclinical Data at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting

Read More

In the News

See All News

PharmaPhorum: Viva in vivo – The next generation of cell therapy is fast approaching

Read More

BioPharma: Astellas teams up with startup Kelonia to make ‘in vivo’ cell therapies

Read More

GEN Edge: Astellas and Kelonia Partner for $800M In Vivo CAR T Cell Therapies

Read More

A positive impact on patients is only a career away.

We’re simultaneously focused on our patient-first mission and proud of our human-first culture. Find out more about working at Kelonia.

Careers

Genetic Medicines for Every Patient.

  • Platform
  • Pipeline
    • Overview
    • Clinical Trial
  • Team
    • Leadership
    • Board of Directors
  • News
  • Careers




© 2025 KELONIA THERAPEUTICS, INC. ALL RIGHTS RESERVED.
PRIVACY POLICY. TERMS OF USE